The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Open accessAbstract
PURPOSE: SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma subtypes, including advanced osteosarcoma. We hypothesized that regorafenib would improve progression-free survival (PFS) in patients with sarcoma and report the results of the osteosarcoma cohort. PATIENTS AND METHODS: This trial enrolled patients with progressive metastatic osteosarcoma with measurable disease by RECIST who had received at least one prior line of therapy. Patients were randomly assigned at a ratio of one to one to regorafenib or placebo. Crossover was allowed at time of disease progression. PFS was the primary end point of the study, which was powered to detect a difference of at least 3 months in median PFS. RESULTS: Forty-two patients from 12 centers were enrolled between September 2014 and May 2018. Median age was 37 years (range, 18 to 76 years). Patients had received an average of 2.3 prior therapy regimens. Ten patients receiving placebo crossed over to active drug at time of progression. Study enrollment was stopped early, after a data safety monitoring committee review. Median PFS was significantly improved with regorafenib versus placebo: 3.6 months (95% CI, 2.0 to 7.6 months) versus 1.7 months (95% CI, 1.2 to 1.8 months), respectively (hazard ratio, 0.42; 95% CI, 0.21 to 0.85; P = .017). In the context of the crossover design, there was no statistically significant difference in overall survival. Fourteen (64%) of 22 patients initially randomly assigned to regorafenib experienced grade 3 to 4 events attributed to treatment, including one grade 4 colonic perforation. CONCLUSION: The study met its primary end point, demonstrating activity of regorafenib in patients with progressive metastatic osteosarcoma. No new safety signals were observed. Regorafenib should be considered a treatment option for patients with relapsed metastatic osteosarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, clinical trials involving TKIs alone are typically with median PFS ranging from 4 to 6 months accompanied with inevitable development of secondary drug resistance1–5.”
From Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, PFS data for IE in relapsed or refractory osteosarcoma were published several decades before the OLIE study46; thus, the PFS estimate for IE relied on limited historical data from other clinically active agents,15,35,36 and IE performed better than expected relative to these assumptions.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“demonstrating a median progression‐free survival (PFS) of 14.8 weeks in Ewing sarcoma, 10 a median PFS of 3.6 months in osteosarcoma, 11 and a nonprogressive rate at 3 months of 54%, significantly better than results with placebo in chondrosarcoma. 12”
From Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial (2025) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies have demonstrated that multi-targeted tyrosine kinase inhibitor (TKIs) can induce varying degrees of objective responses and prolong progression-free survival (PFS)1–5.”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“BS on average show very low TMB: 0.79–1.96 mutations/Mbase in osteosarcoma, 11 , 17 , 18 , 19 ∼0.2 mutations/Mbas in Ewing sarcoma 19 , 20 and <5 mutations/Mbase in chondrosarcoma with some correlation with grade. 21”
From Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial (2025) · cites this paper as [11]
Experimental — accuracy not yet measured
In the citing paper
“Objective response rates were low at 10-15%.”
From Osteosarcoma (2022) · cites this paper as [146]
In the citing paper
“Of note, dose interruptions and reductions of MTKIs have been frequent across these trials secondary to common toxic effects of this drug class, including hand-foot rash syndrome (palmar-plantar erythrodysesthesia), gastrointestinal toxic effects and hypertension 146,147,148,149,150,151 .”
From Osteosarcoma (2022) · cites this paper as [146]
In the citing paper
“Four-month progression-free survival (PFS) ranged from 35% to 70% 146,147,148,149,151 .”
From Osteosarcoma (2022) · cites this paper as [146]
In the citing paper
“Prospective clinical trials evaluated the MTKIs sorafenib, regorafenib, cabozantinib, lenvatinib and apatinib as single agents in patients with relapsed or refractory osteosarcoma, with most enrolled patients falling in the adult age range 146,147,148,149,150,151 (Table 2).”
From Osteosarcoma (2022) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452 · cited 2×
“Six of 22 patients in SARC028 achieved stable disease, resulting in 12-week PFS of 32%, suggesting activity worth further evaluation of immune checkpoint inhibitors in osteosarcoma.(21) Time Since Start of Crossover Treatment (months) C”
BackgroundSelf-citationLink, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203
D'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30006-8 · Cited by 759
Osteosarcoma, Chondrosarcoma, and Chordoma
Whelan, J., & Davis, L. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1743 · Cited by 477
Self-citationBielack, S. S., Smeland, S., Whelan, J. S., Marina, N., Jovic, G., Hook, J. M., Krailo, M. D., Gebhardt, M., Pápai, Z., Meyer, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0734 · Cited by 422
Atkins, M. B., Plimack, E. R., Puzanov, I. J., Fishman, M., McDermott, D. F., Cho, D. C., Vaishampayan, U. N., George, S., Olencki, T. E., Tarazi, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30081-0 · Cited by 372
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359
Grignani, G., Palmerini, E., Ferraresi, V., D’Ambrosio, L., Bertulli, R., Asaftei, S. D., Tamburini, A., Pignochino, Y., Sangiolo, D., Marchesi, E., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71136-2 · Cited by 343
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 267
Kokkali, S., Kyriazoglou, A. I., Mangou, E., Economopoulou, P., Panousieris, M., Psyrri, A. K., Ardavanis, A. S., Vassos, N., & Boukovinas, I. P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031119 · Cited by 17
Liao, Z., Li, M., Wen, G., Wang, K., Yao, D., Chen, E., Liang, Y., Xing, T., Su, K., Liang, C., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00415-7 · Cited by 17
Liu, J.-Y., Zhu, B., Wang, Y., & Sun, X. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01644-7 · Cited by 17
Bishop, M. W. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2025.04.005 · Cited by 16
Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects
Pushpam, D., Garg, V., Ganguly, S., & Biswas, B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s193363 · Cited by 16
Bodea, J., Caldwell, K. J., & Federico, S. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.864790 · Cited by 16
Current topics and management of head and neck sarcomas
Kobayashi, K., Hanai, N., Yoshimoto, S., Saito, Y., & Homma, A. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad048 · Cited by 16
Targeted anti-angiogenesis therapy for advanced osteosarcoma
Zhang, Q., Xia, Y., Wang, L., Wang, Y., Bao, Y., & Zhao, G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1413213 · Cited by 16
MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma
Lietz, C. B., Garbutt, C. C., Barry, W. T., Deshpande, V., Chen, Y., Lozano‐Calderón, S. A., Wang, Y. E., Lawney, B. P., Ebb, D. H., Cote, G. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61236-3 · Cited by 16
Inhibition of osteosarcoma metastasis in vivo by targeted downregulation of MMP1 and MMP9
Doppelt‐Flikshtain, O., Asbi, T., Younis, A., Ginesin, O., Cohen, Z., Tamari, T., Berg, T., Yanovich, C., Aran, D., Zohar, Y., et al. (2024) · Matrix Biology · doi:10.1016/j.matbio.2024.09.002 · Cited by 15
Harrison, D. J., Gill, J. B., Roth, M. E., Zhang, W., Teicher, B. A., Erickson, S. W., Gatto, G., Kurmasheva, R. T., Houghton, P. J., Smith, M. A., et al. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28222 · Cited by 15
Huang, G., Zhang, X., Xu, Y., Chen, S., Cao, Q., Liu, W., Fu, Y., Jia, Q., Shen, J., Yin, J., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04902-8 · Cited by 15
Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma
Perret, A., Dômont, J., Chamseddine, A. N., Dumont, S., Verret, B., Briand, S., Court, C., Lazure, T., Adam, J., Ngo, C., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3610 · Cited by 14
Bad to the Bone: Emerging Approaches to Aggressive Bone Sarcomas
Wood, G. E., Graves, L. A., Rubin, E. M., Reed, D. R., Riedel, R. F., & Strauss, S. J. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390306 · Cited by 16
Self-citationNakano, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316823 · Cited by 14
Sahai, V., Rothe, M., Mangat, P. K., Garrett-Mayer, E. S., Suhag, V., Dib, E. G., Mehmi, I., Kadakia, K. C., Pisick, E. P., Duvivier, H. L., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00527 · Cited by 13
From biology to personalized medicine: Recent knowledge in osteosarcoma
Mohr, A., Costa, M. E. M. D., Fromigué, O., Audinot, B., Balde, T., Droit, R., Abbou, S. D., Khneisser, P., Berlanga, P., Pérez, E., et al. (2024) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2024.104941 · Cited by 13
Liu, Z., Xu, J., Liu, M., Hu, W., Xu, N., & Zhu, D. (2023) · Scientific Reports · doi:10.1038/s41598-023-30412-6 · Cited by 13
Receptor Tyrosine Kinases in Osteosarcoma: 2019 Update
Greenfield, E. M., Collier, C. D., & Getty, P. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_9 · Cited by 13
Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
Bellantoni, A. J., & Wagner, L. M. (2021) · Cancers · doi:10.3390/cancers13143531 · Cited by 13
Ni, M. (2021) · Europe PMC (PubMed Central) · doi:10.7507/1002-1892.202103073 · Cited by 13
Anticancer Molecular Mechanisms of Curcuminoids: An Updated Review of Clinical Trials
Momal, U., Shahbaz, M., Perween, A., Hassan, M. H. U., Naeem, H., Shahid, Z., Hussain, M., Imran, M., Alsagaby, S. A., Abdulmonem, W. A., et al. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71452 · Cited by 12
Lin, Y., Tang, H., Teng, H., Feng, W., Li, F., Liu, S., Liu, Y., & Wei, Q. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111364 · Cited by 12
Mettmann, V. L., Blattmann, C., Friedel, G., Harrabi, S., Kalle, T. V., Kager, L., Kevric, M., Kühne, T., Nathrath, M., Sorg, B., et al. (2024) · Cancers · doi:10.3390/cancers16020275 · Cited by 12
Contemporary surgical management of osteosarcoma and Ewing sarcoma
Callan, A. K., Alexander, J. H., Montgomery, N. I., Lindberg, A. W., Scharschmidt, T. J., & Binitie, O. T. (2024) · Pediatric Blood & Cancer · doi:10.1002/pbc.31374 · Cited by 12
Fleuren, E. D. G., Terry, R. L., Meyran, D., Omer, N., Trapani, J. A., Haber, M., Neeson, P. J., & Ekert, P. G. (2021) · Biomedicines · doi:10.3390/biomedicines9121798 · Cited by 12
Zou, C., Huang, R., Lin, T., Wang, Y., Tu, J., Zhang, L., Wang, B., Huang, J., Zhao, Z., Xie, X., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1382276 · Cited by 12
Controversies and Challenges in the Management of Osteosarcoma—an Indian Perspective
Mittal, A., Pushpam, D., Ganguly, S., Kumar, V. S., Khan, S. A., & Bakhshi, S. (2022) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-021-01486-3 · Cited by 11
Tanaka, K., & Ozaki, T. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac027 · Cited by 11
Long, Z., Huang, M., Liu, K., Li, M., Li, J., Zhang, H., Wang, Z., & Lu, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.662318 · Cited by 11
Shi, B., Chang, J., Sun, X., Ma, X., Zhao, P., Zhou, C., Wang, Y., & Yang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1148735 · Cited by 10
Precision oncology: A primer for pediatric surgeons from the APSA cancer committee
Harris, C. J., Waters, A. M., Tracy, E. T., Christison-Lagay, E. R., Baertschiger, R. M., Ehrlich, P. F., Abdessalam, S. F., Aldrink, J. H., Rhee, D. S., Dasgupta, R. A., et al. (2019) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2019.10.017 · Cited by 11
Tian, Z., Liu, H., Zhao, Y., Wang, X., Ren, H., Zhang, F., Li, P., Zhang, P., Wang, J., & Yao, W. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001016 · Cited by 10
Gaspar, N., Campbell-Hewson, Q., Huang, J., Okpara, C. E., & Bautista, F. (2021) · Future Oncology · doi:10.2217/fon-2021-0743 · Cited by 9
Zhang, Z., Bao, Q., Fu, Y., Wen, J., Li, M., Liu, Z., He, G., Wang, B., Shen, Y., & Zhang, W. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010325 · Cited by 9
Tsuchiya, K., Akisue, T., Ehara, S., Kawai, A., Kawano, H., Hiraga, H., Hosono, A., Hutani, H., Morii, T., Morioka, H., et al. (2024) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2023.11.007 · Cited by 9
Advances in osteosarcoma research: Pathogenesis and emerging therapeutic strategies
Yan, L. ‐., Dong, X., & Chen, S. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105252 · Cited by 10
Circular RNA-Related CeRNA Network and Prognostic Signature for Patients with Osteosarcoma
Man, G., Duan, A., Liu, W., Cheng, J., Liu, Y., Song, J., Zhou, H.-S., & Shen, K. (2021) · Cancer Management and Research · doi:10.2147/cmar.s328559 · Cited by 9
Tian, S., Liu, S., Qing, X., Lin, H., Peng, Y., Wang, B., & Shao, Z. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101349 · Cited by 9
Ji, Y., Harris, M. A., Newton, L. M., Harris, T. J., Fairlie, W. D., Lee, E. F., & Hawkins, C. J. (2024) · BMC Cancer · doi:10.1186/s12885-024-13088-7 · Cited by 8
Hu, X., Fujiwara, T., Sun, Y., Huang, W., & Yan, W. (2023) · European Spine Journal · doi:10.1007/s00586-023-07985-x · Cited by 8
Elamarthi, P. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_110_22 · Cited by 7
Dai, Z., Liu, Z., Yang, R., Cao, W., & Ji, T. (2023) · Biomolecules · doi:10.3390/biom13020327 · Cited by 7
Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma
Zhang, W., Qi, L., Xu, H., Yin, C., Yu, Z., Xu, R., Feng, C., Ren, X., Tu, C., & Li, Z. (2024) · Oncogene · doi:10.1038/s41388-024-03205-y · Cited by 7
Management of Unresectable Localized Pelvic Bone Sarcomas: Current Practice and Future Perspectives
do Brito, J. S., Esperança‐Martins, M., Abrunhosa-Branquinho, A. N., Melo-Alvim, C., Lopes-Brás, R., Janeiro, J., Lopéz‐Presa, D., Fernandes, I., Portela, J., & Costa, L. (2022) · Cancers · doi:10.3390/cancers14102546 · Cited by 7
Tao, K., Yamazaki, F., Kubo, T., Sunami, K., Kumamoto, T., Arakawa, A., Sugiyama, M., Watanabe, Y., Nakajima, M., Shirakawa, N., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00266 · Cited by 8
The paradoxical role of stem cells in osteosarcoma: from pathogenesis to therapeutic breakthroughs
Su, Z., Fang, X., & Duan, H. Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1643491 · Cited by 7
Hu, D., Yu, X., Xu, J., Li, B., Ou, X., & Shi, S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1699287 · Cited by 6
Wang, H., Jin, X., Gao, Y.-H., He, X., Xu, Y., Mu, H., Jiang, Y., Wang, Z., Chen, Y., Zhang, T., et al. (2023) · Cancer Nanotechnology · doi:10.1186/s12645-023-00186-7 · Cited by 6
Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada
Judd, S., Revon‐Rivière, G., Grover, S. A., Deyell, R. J., Vanan, M., Lewis, V. A., Pecheux, L., Zorzi, A. P., Goudie, C., Santiago, R., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7033 · Cited by 6
A comprehensive review of targeting RAF kinase in cancer
Hossain, M. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177142 · Cited by 6
Han, Y., Xie, J., Wang, Y., Liang, X., & Xie, Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-13722-y · Cited by 6
A 10-year bibliometric analysis in the field of osteosarcoma treatment from 2014 to 2023
Shen, Y., Shao, X.-B., Chen, J., & Tang, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-02007-2 · Cited by 6
Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease
Reed, D. R., Hingorani, P., & Anderson, P. M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43032-0_8 · Cited by 6
Self-citationSecondary Osteosarcoma After Bone Marrow Transplant: An Aggressive Disease
Pierobon, M., Mercolini, F., Affinita, M. C., Tombolan, L., Battisti, L., & Bisogno, G. (2020) · Journal of Adolescent and Young Adult Oncology · doi:10.1089/jayao.2020.0054 · Cited by 6
Wang, T., Feng, L., Huang, Y., Qian, G., Yu, W., Hu, H., Ji, T., Tang, L., & Yao, Y. (2022) · Cancer Management and Research · doi:10.2147/cmar.s378264 · Cited by 6
Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials
Reed, D. R., Tulpule, A., Metts, J. L., Trucco, M. M., Robertson‐Tessi, M., O’Donohue, T. J., Cardenas, F. I., Isakoff, M. S., Mauguen, A., Shukla, N. N., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02717 · Cited by 6
Self-citationEmerging treatments for sarcoma: from 2024 onward
Gómez-Puerto, D., Cicala, C. M., Valverde, C. M., & Serrano, C. (2025) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2025.2460525 · Cited by 5
Role of tumor-derived exosomes and immune cells in osteosarcoma progression and targeted therapy
Wang, J., & Shi, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1658358 · Cited by 7
Considerations for Clinical Trial Design in Relapsed and Refractory Osteosarcoma: An FDA Symposium
Wessel, K. M., Janeway, K. A., Davis, L. E., Drezner, N. L., Donoghue, M. B., & Helman, L. J. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3282 · Cited by 5
Self-citationChen, Q., Zhou, X., Jin, J., Feng, J., Xu, Z., Chen, Y., Zhao, H., & Li, Z. (2022) · Journal of Oncology · doi:10.1155/2022/5939158 · Cited by 5
Chen, Y., Zeng, C., Zhang, X., & Hua, Q. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10374-0 · Cited by 5
Precision Oncology in Pediatric Cancer Surgery
Lee, W. G., & Kim, E. S. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2026.05.022 · Cited by 5
Penel, N., Italiano, A., Wallet, J., Chaigneau, L., Verret, B., Firmin, N., Watson, S., Valentin, T., Bompas, E., Bertucci, F., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.024 · Cited by 5
Bioinformatics Analysis Identified Five Widely Expressed Genes Associated with Prognosis in Sarcoma
Tu, B., Jia, Y., & Qian, J. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s352048 · Cited by 5
Ma, H., Wang, X., Zhao, J., Wang, J., Li, Q., Liang, J., Ding, X., Zhang, Y., Zhou, Y., & Hu, H. (2023) · Clinical and Translational Discovery · doi:10.1002/ctd2.202 · Cited by 4
Lai, G., Zhao, X., Chen, Y., Xie, T., Su, Z., Lin, J., Chen, K., & Chen, K. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114260 · Cited by 5
Li, W., Liu, L., Liang, Z., Lai, H., Wu, J., Zhang, H., & Fang, C. (2024) · Medicine · doi:10.1097/md.0000000000037423 · Cited by 4
Regorafenib-Associated Acute Pancreatitis Diagnosed on 18F-FDG PET/CT
Pereira, M., Prakash, A., Puranik, A. D., Purandare, N. C., Shah, S., Agrawal, A., & Rangarajan, V. (2020) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003449 · Cited by 4
Liu, Y., Sun, W., & Li, J. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1938 · Cited by 4
Luminais, S. N., Chen, X. T., Roman, D., Ma, B., Christ, A. B., & Hu, J. S. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-022-03469-6 · Cited by 4
Wang, D., Wang, Y., Wang, H., Yang, Y., Li, L., Liu, Y., & Yin, X. H. (2023) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13763 · Cited by 4
Osteogenic Sarcoma of the Head and Neck: Is Chemotherapy Needed?
Bialick, S., Campoverde, L., Gallegos, J. A. O., Barreto‐Coelho, P., Watson, A., Arora, K. S., Perez, A. R., Lopez, E., Venkat, S. R., Rosenberg, A. E., et al. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01073-4 · Cited by 4
Sugiyama, M., Arakawa, A., Shirakawa, N., Tao, K., Tanimura, K., Nakajima, M., Watanabe, Y., Kumamoto, T., Maniwa, J., Yoneda, A., et al. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30360 · Cited by 4
Wang, W., Chang, J., Ruan, H., Sun, X., Zhao, F., Zhao, P. F., Zhou, C., Tong, J., Guo, S., Shi, Q., et al. (2023) · Materials & Design · doi:10.1016/j.matdes.2023.112269 · Cited by 4
Cardiovascular toxicity of regorafenib for heavily‐treated osteosarcoma
Saito, Y., Makimoto, A., Miura, M., & Yuza, Y. (2020) · Pediatrics International · doi:10.1111/ped.14503 · Cited by 4
Xie, L., Xu, J., Sun, X., Liu, K., Sun, K., Li, Y., Liu, R., Wang, D., Shao, S., Chen, Z., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65467-8 · Cited by 3
Whole-Exome Analysis and Osteosarcoma: A Game Still Open
Chiappetta, C., Rocca, C. D., & Cristofano, C. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413657 · Cited by 3
Zhang, J., Liu, Y., Zhao, X., Xu, R., & Guo, C. (2025) · BMC Cancer · doi:10.1186/s12885-025-15412-1 · Cited by 3
The Role of Adenosine in Overcoming Resistance in Sarcomas
Cruz‐Ramos, M., Cabrera-Nieto, S. A., Murguía‐Pérez, M., & Fajardo-Espinoza, F. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212209 · Cited by 3
Suehara, Y., Kitada, R., Kamio, S., Ogura, K., Iwata, S., Kobayashi, E., Kawai, A., & Khosaka, S. (2024) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2024.10.016 · Cited by 3
Systemic treatment for primary malignant sarcomas arising in craniofacial bones
Bielack, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.966073 · Cited by 3
Reich, M., Dinart, D., Bellio, H., Berchoud, J., Jean‐Denis, M., Bonneau, M., Winter, S., Brunet, M., Duong, R., Nannini, S., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70157 · Cited by 2
Marcinkowska, K. A., Raciborska, A., Obmińska‐Mrukowicz, B., & Śmieszek, A. (2026) · Cancer Management and Research · doi:10.2147/cmar.s562346 · Cited by 2
Sorteberg, A. L., Ek, L., Lilienthal, I., & Herold, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_236-1 · Cited by 2
Liang, G., Duan, C., He, J., & Shi, L. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116826 · Cited by 2
Guan, B., Ge, Z., Zhang, J., & Feng, X. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2433634 · Cited by 2
Mohás, A., Horváth, K., Jakab, Z., & Csóka, M. (2025) · Cancer Medicine · doi:10.1002/cam4.70951 · Cited by 2
Targeting Cell‐Matrix Induced Chemoresistance With Regorafenib in a 3D Model of Osteosarcoma
Rao, R. R., Huang, M. S., Zhang, D. H., Huerta-López, C., Long, C. M., Rodriguez, G. A., Mozipo, E. A. T., Sagi, S., & Heilshorn, S. C. (2025) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37985 · Cited by 2
A novel inflammatory signature for evaluating immune microenvironment status in soft tissue sarcoma
Li, Z., Zheng, H., Liu, L., Fen, Z., Cao, H., Yang, J., & Wei, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.990670 · Cited by 2
The Threat of Medical Misinformation: A Case of Ivermectin Toxicity in a Pediatric Oncology Patient
Gilene, S., Haacker, L., Rutan, H., & Pressey, J. G. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31876 · Cited by 2
Managing axial bone sarcomas in childhood
Meazza, C., Luksch, R., & Luzzati, A. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1891886 · Cited by 2
Morgacheva, D. A., Panova, D. Y., & Belogurova, M. B. (2021) · Russian Journal of Pediatric Hematology and Oncology · doi:10.21682/2311-1267-2021-8-1-57-63 · Cited by 2
Özkan, M., Oflazoğlu, U., Yıldız, Y., Güç, Z. G., Salman, T., Ünal, S., Küçükzeybek, Y., & Alacacıoğlu, A. (2023) · Medicine · doi:10.1097/md.0000000000036435 · Cited by 2
HEY1 promotes the development and metastasis of osteosarcoma through CD44/EGFR/FAK pathway
Liu, Y., Zhang, H., Yi, X., Wang, Z., & Yu, A. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70042 · Cited by 1
Sorteberg, A. L., Ek, L., Lilienthal, I., & Herold, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_236 · Cited by 1
Yang, F., Li, D., Li, B., Yang, T., Zhang, X., Liu, Z., & Zong, L. (2026) · Medicine · doi:10.1097/md.0000000000047284 · Cited by 1
Sarcomas in Adolescents and Young Adults
Greenmyer, J. R., & Allen‐Rhoades, W. A. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01781-8 · Cited by 1
Understanding and Overcoming Osteosarcoma Heterogeneity
Cho, S., Shelmidine, K., & Yustein, J. T. (2026) · Biomolecules · doi:10.3390/biom16060874 · Cited by 1
Ricciardi, G., Fiorentino, V., Tralongo, P., Lentini, M., Pepe, L. R., Zuccalà, V., Ballato, M., Giuffrè, G., Ieni, A., Zampogna, B., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1823738 · Cited by 1
Metadata
- Authors
- Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., Rushing, D., Okuno, S., Reinke, D. K., Riedel, R. F., Attia, S., Mascarenhas, L., & Maki, R. G.
- Affiliations
- Oregon Health & Science University (US)
- Cancer Research And Biostatistics (US)
- Stanford Cancer Institute (US)
- Fred Hutch Cancer Center (US)
- Sarcoma Oncology Center (US)
- Northwestern University (US)
- Levine Cancer Institute (US)
- Moffitt Cancer Center (US)
- Vanderbilt University (US)
- Indiana University Bloomington (US)
- Mayo Clinic (US)
- Sarcoma Alliance for Research through Collaboration (US)
- Duke Medical Center (US)
- University of Southern California (US)
- Northwell Health (US)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2019-06-01
- Volume
- 37
- Issue
- 16
- Pages
- 1424-1431
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC7799443
- OpenAlex
- W2941090871
- Cited by
- 268
- References
- 27
- Citations by year
- 2026: 27 · 2025: 29 · 2024: 35 · 2023: 52 · 2022: 36 · 2021: 44 · 2020: 35 · 2019: 9
- FWCI
- 22.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Funders
- National Cancer Institute (P30CA076292, P30CA014089)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- regorafenib, metastatic osteosarcoma, multikinase inhibitor, progression-free survival, relapsed sarcoma, crossover design, overall survival, drug safety, colonic perforation
- MeSH terms
- Progression-Free Survival, Adolescent, Adult, Aged, Antineoplastic Agents, Bone Neoplasms, Double-Blind Method, Female, Humans, Male, Middle Aged, Phenylurea Compounds, Pyridines, Osteosarcoma, Time Factors, United States, Disease Progression, Cross-Over Studies, Protein Kinase Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
